GHK-Cu
Copper Tripeptide · Gly-His-Lys-Cu²⁺
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The record documents three randomized trials in people: an 86-person evaluator-blinded venous ulcer trial from 1992 where 0.4% copper tripeptide cream showed no advantage over vehicle, a 13-person randomized study after CO2 laser resurfacing where blinded and computer measures found no difference and only the patients' own ratings favored GHK-Cu, and an 18-participant randomized, double-blind, vehicle-controlled split-face serum study for sparse eyebrows that reports few numbers. A 12-week Leyden cream trial is cited only second hand, with its size and results unread. The remaining work is in cells, rats, reviews and solution chemistry.
Counted on the record: 2 human studies, 0 randomized trials, 0 participants, 2 animal studies, 2 lab studies.
The database contains several topical trials, but one sample or source is missing and systemic use has a different evidence scope.
- FDA
- Not FDA drug-approved for any indication. Legal as a cosmetic ingredient (INCI copper tripeptide-1) under MoCRA; injectable is unapproved.
- WADA
- Not on the WADA Prohibited List (2026); no named entry, though broad growth-factor and tissue-repair catch-all categories exist.
Reference only. Not medical advice.
What can go wrong
Topical use is well tolerated; the CIR Expert Panel judged copper tripeptide-1 safe as used in cosmetics at low concentrations. Injectable research-chemical use has no human safety data, raises systemic copper-accumulation concerns, and is contraindicated in Wilson's disease. Systemic longevity claims are not validated.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about GHK-Cu. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
Naturally occurring peptide that binds a copper ion. It helps cells involved in skin and connective tissue remodeling. Best known for skin repair and cosmetic use, topical GHK-Cu is used to support collagen production, skin firmness, wound healing, and the appearance of fine lines and photoaged skin. It is also studied for hair growth, inflammation, tissue repair, and regeneration, but many of these broader uses have much less human evidence.
In your blood since birth. Declining since 30. Search volume up 1,016% year-over-year.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Most proposed GHK-Cu repair mechanisms come from cell and animal studies, not from controlled human research. Human trials have shown mixed results, with no clear objective benefit in some wound-healing studies despite higher patient satisfaction in one trial. Topical absorption, injectable effectiveness, and long-term injectable safety remain uncertain, and cosmetic safety data do not apply to injections.
- Step 1Copper carrierGHK-Cu carries copper, and the body uses it as a repair signal.
- Step 2Collagen and elastinIt tells fibroblasts to build collagen, elastin and the other structural molecules of skin.
- Step 3Clearing and vesselsIt recruits immune cells to clear damaged proteins and encourages small new blood vessels.
- Step 4Gene activityLaboratory work shows it shifts the activity of a broad set of repair and aging related genes.
- Step 5Natural declineBlood levels fall by more than half between age 20 and 60, which is the basis for replacing it.
- Step 6Basal keratinocytesCopper-GHK raises integrin and p63 in basal skin cells, so it acts on the outer layer as well as the dermis.
- Step 7Ground substanceIt shifts wound glycosaminoglycans toward chondroitin and dermatan sulfate, the matrix new tissue is built on.
Most proposed GHK-Cu repair mechanisms come from cell and animal studies, not from controlled human research. Human trials have shown mixed results, with no clear objective benefit in some wound-healing studies despite higher patient satisfaction in one trial. Topical absorption, injectable effectiveness, and long-term injectable safety remain uncertain, and cosmetic safety data do not apply to injections.
Three amino acids bound to one copper ion.
In a laboratory preformulation study, GHK-Cu stayed stable in water and in pH 4.5 to 7.4 buffers for at least two weeks at 60 °C. It broke down under basic and oxidative stress, and to a lesser extent under acid. In plasma, GHK is reported to have a half-life of about 0.5 to 1 hour.
- Type
- Copper tripeptide
- INCI name
- Copper Tripeptide-1
- Origin
- Endogenous
- Forms
- Topical and injectable
- WADA
- Not prohibited
- FDA drug status
- Not approved
Proven On The Skin, Not Beneath It
GHK-Cu is a small copper-carrying peptide that the body uses as a repair signal. When tissue is damaged, or when the peptide is applied to skin, it tells fibroblasts to build collagen, elastin and the other structural molecules of healthy tissue, recruits immune cells to clear out damaged proteins, and encourages small new blood vessels to form. It also acts as an antioxidant and calms inflammatory signaling, and laboratory work shows it shifts the activity of a broad set of repair- and aging-related genes. The body makes it naturally, and plasma levels fall by more than half between age 20 and 60, which is the basis for the idea of replacing it.
How it is taken
Topical
cream Injectable Serum A 0.4% copper-tripeptide complex in a cream vehicle. The trial reports efficacy comparison, not product shelf life. Randomized evaluator-blinded venous-stasis-ulcer trial.
Research (sealed vial)
lyophilizate GHK-Cu in sealed lyophilizate samples. A patent monitored sealed lyophilizate samples for up to 365 days at 35 C and standard humidity. This is not a validated shelf life for an approved product or a post-reconstitution instruction. Patent accelerated-storage experiment.
Injection
GHK+ Cu Recorded because this entry documents injectable use. The Atlas holds no vial, reconstitution or storage detail for it.
Topical
0.2%-0.6% in clinical studie
Safety in detail
- We hold strong safety data for the cream, where the CIR Expert Panel judged copper tripeptide-1 safe in cosmetics and side effects stay rare and mild.
- Copper peptides raise sensitivity to sunlight, so evening use is the usual advice for the cream.
- Repeated injection can build up copper in the body, and people with Wilson's disease should avoid it.
Children and teenagers
There is no pediatric therapeutic use of GHK-Cu and no reason for one. The topical cosmetic form is an adult anti-aging product, irrelevant to children, and while a copper-peptide cream is low-risk, it has no place in a child's routine. The injectable form has no pediatric data, no rationale, and the same source and dosing risks as any gray-market injectable, multiplied in a minor. As with the other peptides, any injectable use in someone under 18 would be unstudied misuse, even though the topical version is comparatively benign.
What people get wrong
Often saidGHK-Cu easily passes through intact skin.
ActuallySkin penetration depends heavily on formulation and delivery. Intact skin can limit absorption.
Often saidGHK-Cu has been proven to reset thousands of genes in people.
ActuallyThis idea comes mostly from lab and mechanistic research, not proven whole-body effects in humans.
Often saidCollagen production means wrinkles, scars, joints and wounds will all improve.
ActuallyCollagen activity is a mechanism, not proof that every claimed benefit happens clinically in people.
Often saidA blue injectable vial tells you it is pure GHK-Cu.
ActuallyColor cannot confirm purity, identity, sterility, potency or formulation quality. Only testing can.
Who profits, and who pushes back
Dermatology research community
Topical evidence is solid; the jump to systemic injection for longevity is a significant and unsupported extrapolation. Gene-activation findings are mostly in vitro.
Clinical pharmacology
High-dose injectable raises real concerns about systemic copper accumulation; contraindicated in Wilson's disease.
Andrew Huberman
Covered extensively including the gene-regulatory data. No GHK-Cu sponsorship.
Dr. Loren Pickart
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Discovered GHK-Cu in 1973; founded Skin Biology, a GHK-Cu product company. Academic credibility genuine; commercial interest also real.
Skincare creator community
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
One of the most affiliate-revenue-driven categories in wellness. Most mentions carry brand affiliate links.
GHK-Cu has two very different money trails. One is large, legitimate and accountable: the global skincare industry, where Copper Tripeptide-1 is a staple active in products ranging from drugstore serums to luxury creams, sold openly by major brands. The other is the gray and compounding market for the injectable: research-peptide vendors selling vials, telehealth and wellness clinics offering "GHK-Cu peptide therapy," and, since the 2026 reclassification, compounding pharmacies preparing it by prescription. So unlike a purely underground peptide, much of GHK-Cu's economy is a normal cosmetics business, and only the injectable, systemic-benefit side carries the familiar gray-market dynamics.
Where the research comes from
| Place | Share of published research |
|---|---|
| USA | 42% |
| France | 20% |
| Germany | 16% |
| Japan | 12% |
| Other | 10% |
Research published from: USA, France, Germany, Japan.
How we got here
GHK-Cu was first isolated from human plasma in 1973 by Loren Pickart and Melvin Thaler, who traced it to a plasma factor that helped older liver tissue synthesize protein like younger tissue. The tripeptide glycyl-L-histidyl-L-lysine binds a single copper(II) ion in a 1:1 complex, and it lives a double life: topically as the widely used cosmetic ingredient Copper Tripeptide-1 (sold under trade names such as Iamin and Lamin) for skin repair and collagen support, and separately as an injectable research chemical studied for tissue regeneration.
GHK was discovered in 1973 by Loren Pickart, who isolated the tripeptide from human plasma and later identified its copper-bound form as a repair signal. A landmark 1988 paper established that it stimulates collagen synthesis, and through the 2000s controlled cosmetic trials, notably by Leyden, built its reputation as an anti-aging skincare active, cementing Copper Tripeptide-1 as an industry staple. In the 2010s, gene-expression and longevity papers, several from Pickart himself, drove a second wave of interest in systemic and injectable use that ran ahead of the human evidence. The injectable form was restricted from compounding in 2023 and reopened in the 2026 peptide reclassification, leaving GHK-Cu in a lasting dual existence as both a proven cosmetic and an unproven injectable.
Discovery and copper-binding research
1973 to 1980
Early reports traced GHK to plasma and explored its association with metals and possible role in copper uptake.
- 1973Pickart et al., synthetic tripeptide and liver-cell growthThe first report described a small plasma tripeptide identified as GHK through liver-cell experiments, not skincare research. The report noted that older tissue behaved more like younger tissue.
- 1980Pickart and Thaler, GHK association with plasma metalsThe paper reported an association between GHK and copper and iron in plasma. It described GHK as likely acting as a biologically active metal-binding complex.
- 1980Pickart et al., GHK and copper uptakeThe authors proposed that the plasma tripeptide might function by facilitating copper uptake into cells.
Laboratory foundation
1988 to 1988
Cultured fibroblasts increased collagen synthesis after GHK-Cu exposure.
- 1988Maquart et al., GHK-Cu and fibroblast collagenCultured fibroblasts increased collagen synthesis after exposure to GHK-Cu. This was a cell-culture finding, not a clinical skin or wound outcome.
- October 10, 1988Maquart and Pickart report GHK-Cu collagen work in FEBS LettersA biochemistry laboratory at the Faculty of Medicine in Reims, France, led by François-Xavier Maquart and joined by Loren Pickart, published a short paper on GHK-Cu and collagen synthesis by fibroblasts grown in the lab. It is a cell-culture study, and its findings are recorded as claims.
Human topical studies and patents
1992 to 2006
Topical studies and patents explored wound healing, skin creams, hair growth, and cosmetic applications, with mixed human findings.
- 1992Bishop et al., randomized venous-ulcer trialThe randomized ulcer trial found no advantage for 0.4% copper-tripeptide cream over vehicle. This was a prospective randomized, evaluator-blinded clinical trial in people with chronic venous stasis ulcers. Ninety-three participants were randomized and 86 completed/evaluated the trial.
- 1996US Patent 5,538,945AThe patent described stimulation of hair growth by peptide copper complexes, an early commercialization milestone beyond wound repair.
- 1998Abdulghani et al., topical creams and skin ultrastructureSkin-biopsy findings suggested GHK-Cu increased procollagen in more volunteers than the vitamin C or tretinoin comparators. The study added to its topical skin-aging case.
- 2006Miller et al., CO2 laser-resurfaced skin studyThe study was conducted as University of New Mexico fellowship research and received the 2005 AAFPRS John Orlando Roe Award. It used a ProCyte copper-tripeptide regimen, but commercial sponsorship is not clearly disclosed in accessible records although ProCyte/NEOVA sponsored the research.
- 2005Leyden facial and eye cream trial, as cited by reviewsLater reviews cite a 12-week randomized clinical trial of a GHK-Cu facial and eye cream by J. J. Leyden, printed as Dermatologic Surgery 31, no. 7 (2005): 809-816. The address followed led to the reference list of a 2026 review, not to the trial itself, so the trial's abstract, size and results have not been read.
- August 1992Bishop venous ulcer trial publishedBishop and colleagues, from the Division of Plastic Surgery at the University of Texas Medical Branch in Galveston, published a prospective, randomized, evaluator-blinded trial comparing a 0.4% tripeptide copper complex cream, 1% silver sulfadiazine cream and an inert placebo cream in people with venous stasis ulcers. It is one of the earliest published randomized trials of a copper tripeptide in people.
- 2006Miller laser-resurfacing aftercare study publishedMiller and colleagues published a randomized study in which people who had CO2 laser resurfacing of the skin around the mouth were assigned to aftercare routines with or without GHK-Cu skin care products. Thirteen people completed it, and its findings are recorded as claims.
Reviews and topical patents
2015 to 2024
A review brought together regenerative findings, while later patents described cosmetic and topical formulations.
- 2015RU2571691C2, Russian cellulite patent references GHK-CuJohnson & Johnson patent for Paulownia-based cellulite treatment cited GHK-Cu as a possible collagen-promoting ingredient, but GHK-Cu itself was not the patented treatment.
- 2024US Patent 12,151,031 B2The patent described a topical copper tripeptide composition. Its focus was topical and transdermal delivery and formulation, rather than proving systemic injectable benefits.
- September 29, 2023FDA moves GHK-Cu into Category 2A compliance-consulting page reports that an FDA update of September 29, 2023 placed GHK-Cu, with limitations, on the Category 2 bulks list, which restricts compounding. This comes from a consultant's summary that points to the FDA list. The FDA list itself was not opened.
2020s
From 2026
- 2026GHK-Cu injection nomination withdrawnA Frier Levitt law-firm article states that the nomination of GHK-Cu for injection was withdrawn and that GHK-Cu was taken off Category 2. This comes from a law firm's summary that points to the FDA action, not from the FDA docket itself.
The numbers behind the grade
- Cosmetic name
- Copper Tripeptide-1
- Topical evidence
- Strong
- Injectable evidence
- Thin
- WADA
- Not banned
- FDA drug
- Not approved
- Age decline
- ~60% by 60
The people taking it
Two separate audiences use it. The cream reaches a broad, mainly female skincare market across adult ages, and the injection reaches a much smaller group of biohackers, longevity enthusiasts and wellness-clinic patients.
One of the most-searched peptides in both skincare and wellness, and arguably the most famous "copper peptide" in the world. It enjoys a rare dual fame: a mainstream, normalized cosmetic ingredient on one hand, and a biohacker and longevity favorite in injectable form on the other.
GHK-Cu reaches two largely separate audiences. The topical-cosmetic user base is broad and mainstream, skews female, and spans a wide adult age range within the enormous anti-aging skincare market. The injectable user base is much smaller and looks like the rest of the peptide scene: biohackers, longevity enthusiasts, people seeking hair regrowth, and the wellness-clinic crowd, with no reliable demographic data on who self-injects. The cosmetic side is one of the most normalized peptide uses in the world; the injectable side sits in the familiar gray zone.
Used worldwide as a topical cosmetic for collagen support and anti-aging, where the evidence is genuinely good, and used more narrowly in injectable or compounded form for hair, healing and systemic longevity goals, where it is not. One of the few peptides here that is not prohibited in sport.
Set against the alternatives
Among cosmetic peptides, GHK-Cu has one of the deepest and oldest human evidence bases, ahead of newer wrinkle peptides like the Matrixyl palmitoyl peptides or the relaxing peptide argireline, and some trials have compared it favorably with established actives, though claims that it beats retinoids outright should be read with caution. Compared with the injectable healing peptides it is so often stacked with, BPC-157 and TB-500, GHK-Cu actually has more human evidence, because its topical trials are real, whereas those two have essentially none in humans. The popular GLOW stack combines all three for skin and healing, but no controlled trial has tested that blend, and the strength of GHK-Cu's own topical data does not transfer to an unstudied injected combination.
What we do not know
- Whether injected or systemic GHK-Cu produces any of the whole-body benefits claimed, beyond what the topical form does for skin.
- What the long-term safety of injectable use is, including any risk of copper accumulation.
- Whether the broad gene-expression effects seen in the lab translate into real clinical outcomes in people.
- How its hair-growth effects compare with established treatments in proper trials.
- Whether the advisory review expected by early 2027 keeps the compounding pathway open.
What could change
The advisory reviewAn expected 2027 committee review will shape whether the injectable compounding pathway stays open.Systemic evidenceWhether anyone runs real human trials of injected GHK-Cu for the whole-body claims is the key scientific question.Hair-loss formulationsContinued interest in copper-peptide products for hair, ideally tested against established options.Combination cosmeticsPairing GHK-Cu with other actives (like hyaluronic acid) where early synergy data exists.A persistent dual lifeThe likeliest future is continued coexistence as a proven cosmetic and an unproven injectable.
Legal status
GHK-Cu exists in three access lanes, and they could not be more different. As a cosmetic (Copper Tripeptide-1) it is sold over the counter worldwide in serums and creams, no prescription needed. As a compounded therapeutic it can be prepared by a licensed pharmacy with a prescription; injectable GHK-Cu had been blocked from compounding in 2023 but was reopened in 2026 (reopening is not drug approval). And as a research chemical it is sold online by peptide vendors as research-use-only. It is not an FDA-approved drug for any indication, and it is not banned in sport. For most people the topical route is both the safest and the best-evidenced.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Topical copper-peptide products are available from ordinary skincare retailers under the name Copper Tripeptide-1, with no prescription required, and this is the route with the strongest evidence behind it. Injectable or prescription-strength topical GHK-Cu comes through a telehealth or wellness clinic and a licensed compounding pharmacy. Research-chemical vendors sell vials online as research-use-only, where an independent certificate of analysis is the only real quality check. The cautious, evidence-aligned choice for most people is a topical cosmetic product.
The topical cosmetic form ranges widely, from budget serums around $20 to premium products over $200 a bottle. Gray-market research vials are inexpensive per milligram, often in the range of one to a few dollars. Compounded injectable or topical GHK-Cu from a pharmacy costs more once prescription and pharmacy fees are added, but offers better quality assurance than a research vial.
Cosmetic-grade copper peptide comes from established ingredient suppliers and is regulated as a cosmetic. Injectable and bulk material in the gray market is synthesized mostly in China and sold for research use, with the usual uncertainty about identity, dose and purity, so a current third-party certificate of analysis matters. Compounded product from a licensed pharmacy sits in between, with more oversight than a research vial.
Cosmetic raw material (global)Copper Tripeptide-1 is produced by legitimate cosmetic-ingredient suppliers and formulated into skincare worldwide, regulated as a cosmetic and freely traded.Compounding pharmacies (US)Since injectable GHK-Cu returned to compounding eligibility in 2026, licensed 503A pharmacies can prepare it with a prescription, a more controlled source than research vials.China and research vendorsThe cheapest injectable and bulk material flows from overseas synthesis, predominantly China, sold online as research-use-only.One molecule, three lanesThe same chemistry moves through a regulated cosmetic chain, a prescription compounding chain, and an unregulated research-vendor chain; the route, not the molecule, sets the rules.
At a glance
- Amino acid sequence
- Gly-His-Lys (glycyl-L-histidyl-L-lysine)
- Amino acids
- 3
- Plasma at age 20
- ~200 ng/mL
- Plasma at age 60
- ~80 ng/mL
- Found in
- Plasma, saliva, urine
- Copper Magnet
- GHK has an incredibly high affinity for copper. It will actually compete successfully with other powerful biological chelators (like human serum albumin) to grab and bind copper ions in the body.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about GHK-Cu.
Nothing outstanding on this one.
Sources
GHK peptide biology, gene modulation, and topical trial summary; plasma GHK declines from ~200 to ~80 ng/mL with age; Pickart isolated GHK in 1973
CIR Expert Panel safety assessment: copper tripeptide-1 / tripeptide-1 and metal salts are safe as used in cosmetics at low concentrations (<10 ppm)
CIR full safety monograph confirming copper tripeptide-1 among reviewed cosmetic peptides and negative safety test data
Chemical identity: glycyl-L-histidyl-L-lysine copper complex (prezatide copper), molecular formula C14H23CuN6O4+, PubChem CID 71587328, cosmetic use
INCI listing of copper tripeptide-1 as a cosmetic ingredient
Broader review of GHK-Cu regenerative and protective actions and gene-data claims; attribution to Pickart and Margolina
GHK-Cu is not FDA drug-approved for any indication; legal as a cosmetic active (copper tripeptide-1) under MoCRA; injectable research vials are not for human use
GHK-Cu not named on the WADA Prohibited List; primarily topical, not associated with performance-enhancing use
Copper peptide topical skin-aging trials summarized (Leyden, Finkey) with sample sizes and outcomes; discovery and cosmetic-industry adoption context
PRIME Journal, 'Copper tripeptide GHK-Cu and Regenerative Aesthetics'
In a prospective randomized evaluator-blinded trial of 86 people with venous stasis ulcers, a 0.4% copper-tripeptide cream showed no advantage over placebo, while a 1% silver sulfadiazine cream reduced ulcer size by a statistically significant margin compared with both the copper-tripeptide cream and placebo, though the abstract provides no effect sizes or p-values.
A 2006 randomized study of aftercare following CO2 laser resurfacing around the mouth in 13 people found that GHK-Cu skin care products did not reduce redness faster than routine aftercare, with neither computer image analysis nor blinded evaluators detecting a statistically significant difference between groups. Patients using GHK-Cu products reported significantly greater improvement in overall skin quality on a validated questionnaire, though blinded evaluators and computer measures found no objective difference between the groups.
In cultured fibroblasts, GHK-Cu increased collagen synthesis, with the rise beginning at extremely dilute concentrations between 10^-12 and 10^-11 molar and greatest at 10^-9 molar, independent of changes in cell number. This is a laboratory finding in cells grown in a dish, not in people, and the abstract provides no information on fibroblast source, number of cultures tested, or statistical values. The authors suggest that the same three-amino-acid sequence GHK found within the alpha 2 chain of type I collagen might be released by enzymes at a wound site and could help healing, though the study did not test this hypothesis.
Patent examples test sealed lyophilizate and aqueous GHK-Cu preparations.
A review describes GHK and its copper complex drawing in repair cells, suppressing free radicals and inflammatory mediators, and raising synthesis of collagen, elastin, metalloproteinases, vascular endothelial growth factor, fibroblast growth factor 2 and nerve growth factor.
In 24 adult male Sprague-Dawley rats with ischemic full-thickness wounds, a topical glycyl-L-histidyl-L-lysine copper complex reduced wound area by 64.5% at day 13, compared with 45.6% for the vehicle base alone and less for untreated controls. Wound area shrank significantly more with the copper complex gel than with no treatment on days 3 to 5, 6 to 9, and 11 to 13, though the gel base alone did not differ significantly from no treatment. On days 6, 10, and 13, wounds treated with the copper complex gel held significantly lower levels of TNF-alpha, an inflammation signal, and of MMP-2 and MMP-9, enzymes that break down tissue, than untreated wounds. These are animal results, not results in people.
A review in a cosmetics journal collects reported skin regenerative and anti-cancer actions of copper peptides. The journal carries no PubMed indexing, and the review shares its first author with the other two GHK reviews on this page.
In cultured human keratinocytes and in skin equivalent models, copper-GHK increased keratinocyte proliferation, raised PCNA and p63 positivity, and increased integrin alpha6 and beta1 expression.
In rat experimental wounds, repeated 2 mg injections of the GHK copper complex increased wound tissue production, type I collagen and glycosaminoglycans, and raised the accumulation of chondroitin sulfate and dermatan sulfate.
A clinical trial titled Topical GHK-Cu Gel for Acute Skin Wound Healing is registered on ClinicalTrials.gov under the number NCT07437586. The registry text read for this library did not show the trial's enrollment, sponsor, status or results, so none of those are reported here.
Topical GHK-Cu Gel for Acute Skin Wound Healing, NCT07437586
A 2012 study in Genome Medicine identified 127 genes linked to emphysema damage in lung tissue from smokers with COPD, finding that inflammation-related genes rose with damage while tissue repair genes fell, including those for the TGF-beta pathway, actin organization and integrin signaling. Using a database that matches gene patterns to compounds, the researchers predicted GHK could reverse this damage pattern based on computer analysis of donated lung tissue. In cultured human fibroblasts, GHK reproduced gene patterns normally activated by TGF-beta, organized the actin skeleton, and raised integrin beta 1 levels. However, GHK was not given to people in this study.
A 2007 lab study tested AHK-Cu, a tripeptide-copper complex related to GHK-Cu that differs by having alanine instead of glycine. At very low concentrations from 10 to the minus 12 to 10 to the minus 9 molar, AHK-Cu made human hair follicles kept alive outside the body grow longer and increased growth of cultured dermal papilla cells, the cells at the base of the hair follicle. At 10 to the minus 9 molar, AHK-Cu lowered the number of dying dermal papilla cells, though not significantly, and showed markers of reduced programmed cell death including higher Bcl-2 to Bax ratio and lower levels of cleaved caspase-3 and PARP. These are cell culture results with no sample counts or statistical values reported, not tests of hair growth in people.
A 1973 paper in Biochemical and Biophysical Research Communications is titled 'A synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells'. Hepatoma is a liver cancer. Its PubMed record has no abstract, so it shows only the title and journal, with no methods or results. The entry says the 1973 discovery paper appeared in Nature, but this record names a different journal. This record alone does not confirm the account that GHK was isolated from human plasma.
A 1980 paper by Pickart and Thaler reports that GHK in blood plasma is bound to copper and iron ions and may act as a peptide-metal complex. In solution at body pH, GHK bound copper, cobalt, iron, molybdenum, manganese, nickel and zinc, but showed no affinity for calcium, potassium or sodium. In cultured hepatoma cells grown with reduced serum, copper, iron, cobalt and zinc alone caused cells to flatten and slowed DNA synthesis; adding GHK at nanomolar concentrations reversed these effects and stimulated the cells to adhere and grow, with copper and iron being the most active metals when combined with GHK. These results come from cancer cells in culture and tell nothing about effects in people.
A 1983 Biochemical Journal study by Laussac, Haran and Sarkar used nuclear magnetic resonance and electron paramagnetic resonance spectroscopy to examine how copper(II) binds the tripeptide GHK. The NMR signal broadening came from minor copper-peptide forms that swap quickly rather than the main form in solution, and the authors caution that this approach may not give structural information about the main form. EPR readings across a wide range of acidity came almost entirely from copper-peptide forms that hold the copper in a similar way, with fine detail in the signal appearing at pH 5.5 and sharpest between pH 6.0 and 9.6, though this test-tube chemistry tells nothing about effects in the body.
A 2001 study compared how copper binds to GHK and two lab-made analogues where histidine was replaced by L-spinacine or L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, using potentiometry, calorimetry, UV-visible spectroscopy and other methods. All three peptides formed copper complexes that differed in composition and stability, with evidence of forms holding two copper ions. Solution chemistry suggested that GHK's lysine side group helps hold copper only under alkaline conditions, while at normal body pH that group remains free and may be available to interact with cell receptors, though this was not measured in cells or people. When tested for breakdown by enzymes in human serum, the two lab-made versions showed no significant breakdown for at least 3 hours, though this serum test does not indicate how a finished GHK-Cu product behaves in people.
A team at the School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Thailand, tested a 2% GHK-Cu serum for sparse eyebrows, called eyebrow hypotrichosis. The study was randomized, double-blind and vehicle-controlled, with a split-face design that compares the two sides of each person's face. The journal page reports results for 18 participants. The authors' background states that evidence on copper peptides for eyebrows has been limited. The abstract gives few numbers for the comparison between sides. The study covers eyebrows only, not scalp hair loss or injected GHK-Cu.
An FDA list dated May 14, 2026 covers bulk drug substances nominated for compounding under section 503A. It places GHK-Cu in Category 1 for all routes except injection, though this categorization is part of FDA's review process and is not approval of GHK-Cu as a drug. The same list states that the nominator withdrew the nomination of GHK-Cu for injectable routes, meaning injectable GHK-Cu did not become eligible for compounding through this process.
FDA identifies GHK-Cu for injectable routes as a bulk drug substance that may present significant safety risks, citing possible immune reactions linked to peptide aggregation and impurities, along with limited safety information in people.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
An FDA 503A categories update dated September 27, 2024 listed GHK-Cu for injectable routes in Category 2. Later FDA records describe the injectable nomination as withdrawn. This document therefore shows the earlier listing, not the current status.
The World Anti-Doping Agency's 2026 Prohibited List does not name GHK or GHK-Cu. The list does include broad groups, among them certain growth factors and substances that change growth-factor activity. Because of this, the absence of a named entry does not by itself show that using GHK-Cu could never lead to an anti-doping violation.
The studies that matter
Maquart et al, FEBS Letters1988
The foundational finding that GHK-Cu stimulates collagen synthesis in human fibroblast cultures, the basis for everything that followed.
Leyden, Dermatologic Surgery2005
A randomized 12-week trial of a GHK-Cu facial and eye cream showing improvement in photodamaged skin, with histologic evidence.
Facial-cream trial (71 women, photoaging)2000s
Three months of daily copper-peptide cream increased skin density and thickness and reduced sagging and fine lines.
Eye-cream trial (41 women)2000s
A GHK-Cu eye cream improved lines, density and thickness more than both placebo and a vitamin-K cream.
Finkey, J Cosmetic Dermatology2019
GHK-Cu combined with low-molecular-weight hyaluronic acid synergistically boosted collagen IV.
Hair-growth and wound-healing studies1990s-2010s
In vitro work showed copper-tripeptide effects on hair-follicle cells, and animal studies showed faster wound healing and more collagen.
Injectable, systemic human trialsnone completed
The whole-body and longevity claims rest on cell, gene-expression and topical data; no completed human trial validates injected GHK-Cu for systemic outcomes.